| __timestamp | CRISPR Therapeutics AG | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 3401685 |
| Thursday, January 1, 2015 | 12573000 | 4284228 |
| Friday, January 1, 2016 | 42238000 | 3581295 |
| Sunday, January 1, 2017 | 69800000 | 4838300 |
| Monday, January 1, 2018 | 113773000 | 24891534 |
| Tuesday, January 1, 2019 | 179362000 | 31347891 |
| Wednesday, January 1, 2020 | 266946000 | 17480747 |
| Friday, January 1, 2021 | 438633000 | 34710152 |
| Saturday, January 1, 2022 | 461645000 | 108459978 |
| Sunday, January 1, 2023 | 387332000 | 181563523 |
| Monday, January 1, 2024 | 320653000 | 176326321 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology, innovation is the key to staying ahead. Two companies, Opthea Limited and CRISPR Therapeutics AG, have been at the forefront of this race, each with a unique approach to research and development (R&D) spending.
From 2014 to 2023, CRISPR Therapeutics AG has consistently outpaced Opthea Limited in R&D investment, with a peak in 2022 where their spending was approximately 2.5 times higher. However, Opthea Limited has shown remarkable growth, increasing its R&D expenses by over 500% from 2014 to 2023.
While CRISPR Therapeutics AG leads in absolute spending, Opthea Limited's rapid growth in R&D investment signals a strong commitment to innovation. As we look to the future, these trends highlight the dynamic nature of the biotech industry and the critical role of strategic investment in shaping its trajectory.
Comparing Innovation Spending: Eli Lilly and Company and Opthea Limited
Research and Development: Comparing Key Metrics for United Therapeutics Corporation and Opthea Limited
Research and Development Expenses Breakdown: United Therapeutics Corporation vs CRISPR Therapeutics AG
Analyzing R&D Budgets: Insmed Incorporated vs CRISPR Therapeutics AG
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs CRISPR Therapeutics AG
Blueprint Medicines Corporation vs Opthea Limited: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Opthea Limited and CymaBay Therapeutics, Inc.
Analyzing R&D Budgets: Opthea Limited vs Veracyte, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
CRISPR Therapeutics AG vs Galapagos NV: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.